UnitedHealth posted Q3 2026 revenue of $112.69B and adjusted EPS of $4.69, both above estimates of $111.03B and $4.12, and raised 2026 adjusted EPS guidance to at least $20.50 from a prior view of $19.50 to $20.
The beat on both revenue and EPS, plus the raised full-year guidance, signals stronger underlying earnings momentum and more confidence from management about the rest of the year. This is a single-company result and does not point to a clear, sourced move in broader FX, rates, metals, energy or index markets.